Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Benign Prostatic Hyperplasia Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Benign Prostatic Hyperplasia Therapeuticsmarket, defines the market attractiveness level of Benign Prostatic Hyperplasia Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Benign Prostatic Hyperplasia Therapeutics industry, describes the types of Benign Prostatic Hyperplasia Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Benign Prostatic Hyperplasia Therapeutics market and the development prospects and opportunities of Benign Prostatic Hyperplasia Therapeutics industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Benign Prostatic Hyperplasia Therapeutics market in Chapter 13.
By Player:
Teva Pharmaceutical Industries Limited
Eli Lilly and Company
Astellas Pharma
Allergan plc
GlaxoSmithKline plc
Boehringer Ingelheim Pharma GmbH & Co KG
Pfizer
Merck & Co
Abbott Laboratories
Sanofi
By Type:
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
By End-User:
Mono drug therapy
Combination drug therapy
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Benign Prostatic Hyperplasia Therapeutics Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Benign Prostatic Hyperplasia Therapeutics Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Benign Prostatic Hyperplasia Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Benign Prostatic Hyperplasia Therapeutics Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Benign Prostatic Hyperplasia Therapeutics Market Analysis and Outlook to 2022
-
7.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.2 United States Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.4 China Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.5 Japan Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.6 India Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
7.7 South Korea Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
8 Region and Country-wise Benign Prostatic Hyperplasia Therapeutics Market Analysis and Outlook to 2028
-
8.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.2 United States Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.3 Europe Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.4 China Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.5 Japan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.6 India Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
8.7 South Korea Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
9 Global Benign Prostatic Hyperplasia Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Alpha blocker Consumption and Growth Rate (2017-2022)
-
9.1.2 Global 5-Alpha reductase inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Phosphodiesterase-5 inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Mono drug therapy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Combination drug therapy Consumption and Growth Rate (2017-2022)
10 Global Benign Prostatic Hyperplasia Therapeutics Market Outlook by Types and Applications to 2028
-
10.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Alpha blocker Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global 5-Alpha reductase inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Phosphodiesterase-5 inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Mono drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Combination drug therapy Consumption Forecast and Growth Rate (2022-2028)
11 Global Benign Prostatic Hyperplasia Therapeutics Import and Export Analysis (Top 5 Countries)
-
11.1 Global Benign Prostatic Hyperplasia Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Benign Prostatic Hyperplasia Therapeutics Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Benign Prostatic Hyperplasia Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Benign Prostatic Hyperplasia Therapeutics Market Competitive Analysis
-
14.1 Teva Pharmaceutical Industries Limited
-
14.1.1 Teva Pharmaceutical Industries Limited Company Details
-
14.1.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.2 Eli Lilly and Company
-
14.2.1 Eli Lilly and Company Company Details
-
14.2.2 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.3 Astellas Pharma
-
14.3.1 Astellas Pharma Company Details
-
14.3.2 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.4 Allergan plc
-
14.4.1 Allergan plc Company Details
-
14.4.2 Allergan plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.5 GlaxoSmithKline plc
-
14.5.1 GlaxoSmithKline plc Company Details
-
14.5.2 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.6 Boehringer Ingelheim Pharma GmbH & Co KG
-
14.6.1 Boehringer Ingelheim Pharma GmbH & Co KG Company Details
-
14.6.2 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.7 Pfizer
-
14.7.1 Pfizer Company Details
-
14.7.2 Pfizer Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.8 Merck & Co
-
14.8.1 Merck & Co Company Details
-
14.8.2 Merck & Co Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Merck & Co Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.9 Abbott Laboratories
-
14.9.1 Abbott Laboratories Company Details
-
14.9.2 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Service
-
14.10 Sanofi
-
14.10.1 Sanofi Company Details
-
14.10.2 Sanofi Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Benign Prostatic Hyperplasia Therapeutics
-
Figure Benign Prostatic Hyperplasia Therapeutics Picture
-
Table Global Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure United States Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alpha blocker Consumption and Growth Rate (2017-2022)
-
Figure Global 5-Alpha reductase inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Phosphodiesterase-5 inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Mono drug therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Combination drug therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Alpha blocker Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 5-Alpha reductase inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Phosphodiesterase-5 inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Mono drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Combination drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Benign Prostatic Hyperplasia Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Benign Prostatic Hyperplasia Therapeutics Export by Region (Top 5 Countries) (2017-2028)
-
Table Teva Pharmaceutical Industries Limited (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Eli Lilly and Company (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Astellas Pharma (Foundation Year, Company Profile and etc.)
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Allergan plc (Foundation Year, Company Profile and etc.)
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table GlaxoSmithKline plc (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Boehringer Ingelheim Pharma GmbH & Co KG (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Merck & Co (Foundation Year, Company Profile and etc.)
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Abbott Laboratories (Foundation Year, Company Profile and etc.)
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Service
-
